Condition: Breast Cancer · Sponsor: University of Hawaii
The objective is to better identify suspicious breast lesions that need to be biopsied for malignancy in women currently recommended for biopsy. The long-term goal is to reduce unnecessary biopsies and increase biopsy yield. To do this, the investigators have developed an innovative way to use FDA-approved breast imaging protocols to acquire multispectral images to measure the composition of suspicious breast lesions. The central hypothesis is that breast tissue composition in combination with analysis of morphological and textural tissue characteristics on digital breast tomosynthesis (DBT) imaging will yield significantly higher breast cancer specificity than conventional interpretation of DBT alone.
This description comes directly from the study's public registry record.
John A Shepherd, PhD · 808-440-5234 · johnshep@hawaii.edu
Leila Kazemi · 808-440-5231 · lkazemi@hawaii.edu
Always discuss trial participation with your own doctor first.
| H. Lee Moffitt Cancer Center & Research Institute, Inc. | Tampa, Florida, United States | Recruiting |
| Hawaii Radiology Associates, LTD (East Hawaii Women's Imaging Center) | Hilo, Hawaii, United States | Recruiting |
| The Queen's Medical Center | Honolulu, Hawaii, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05369546